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To identify candidate genes relevant for prostate tumour prognosis and progression, we performed an exhaustive gene search in
seven previously described genomic-profiling studies of 161 prostate tumours, and four expression profiling studies of 61 tumours.
From the resulting list of candidate genes, six were selected for protein-expression analysis based on the availability of antibodies
applicable to paraffinised tissue: fatty acid synthase (FASN), MYC, b-adrenergic receptor kinase 1 (BARK1, GRK2) the catalytic
subunits of protein phosphatases PP1a (PPP1CA) and PP2A (PPP2CB) and metastasis suppressor NM23-H1. These candidates were
analysed by immunohistochemistry (IHC) on a tissue microarray containing 651 cores of primary prostate cancer samples and benign
prostatic hyperplasias (BPH) from 175 patients. In univariate analysis, expression of PP1a (P¼0.001) was found to strongly correlate
with Gleason score. MYC immunostaining negatively correlated with both pT-stage and Gleason score (Po0.001 each) in univariate
as well as in multivariate analysis. Furthermore, a subgroup of patients with high Gleason scores was characterised by a complete loss
of BARK1 protein (P¼0.023). In conclusion, our study revealed novel molecular markers of potential diagnostic and therapeutic
relevance for prostate carcinoma.
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Prostate cancer is the most commonly diagnosed noncutaneous
neoplasm among males in Western countries and is estimated to
result in 28900 deaths this year in the US alone (Jemal et al, 2003).
Serum prostate specific antigen (PSA) level and clinico-patholo-
gical factors like Gleason score and pT-stage are accepted
diagnostic and prognostic factors, which, however, often fail to
predict accurately the clinical outcome in individual cases
(Frydenberg et al, 1997). Therefore, it is of major importance to
further elucidate the molecular aberrations present in this
disease. This should not only provide a better understanding of
the pathomechanisms of this tumour, but also contribute to the
development of better diagnostic tools and improved therapeutic
strategies.
Array-based screening approaches are widely used to define
tumour-specific aberration patterns of the genome and of gene
expression. Comparative genomic hybridisation (CGH) and high-
resolution array CGH have been successfully applied for the
comprehensive screening of whole tumour genomes. In prostate
carcinoma, several of these imbalances were shown to correlate
with prostate cancer progression. For example, gains of chromo-
somes 7 and 8q were found to increase with tumour stage and
grade (Alers et al, 2001). However, owing to the large size of
imbalanced chromosomal regions, the group of genes to be
considered as possible candidates is usually in the range of several
hundreds. Therefore, additional analyses have to be performed in
order to identify those genes that represent the most critical
candidates relevant for tumour development.
In the present study, we aimed to identify novel relevant
biomarkers in prostate carcinoma by combining the results of
genomic screening as well as expression profiling data. First,
an exhaustive search for imbalanced chromosomal regions from
seven CGH and array CGH studies was performed (Sattler et al,
1999; Alers et al, 2001; Verdorfer et al, 2001; Zitzelsberger et al,
2001; Steiner et al, 2002; Wolter et al, 2002; Paris et al, 2003). Next,
the results were compared to a recent meta-analysis of four
independent expression array data sets (Rhodes et al, 2002) in
order to define candidate genes located within regions recurrently
changed in copy number. Of the candidate genes identified,
six were selected for protein-analysis based on the availability
of antibodies suitable for paraffin-embedded tissue. Detailed
immunohistochemical analysis was performed in a cohort of
prostate carcinomas using tissue microarray technology. The
correlation of protein expression with Gleason score and pT-stage
indicated new candidates involved in the pathomechanisms of
prostate cancer and potential diagnostic markers.
MATERIALS AND METHODS
Patient material
Formalin-fixed, paraffin-embedded primary prostate adenocarci-
nomas resected between 1998 and 2003 were diagnosed in the
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sDivision of cellular and molecular pathology at the German Cancer
Research Centre, Heidelberg. All samples were taken from a
tumour bank, and approval to link laboratory data to clinical data
was obtained from the Institutional review board. This procedure
is compliant with the official statement of the National ethics
council of the Federal Government of Germany (March 2004).
The study included 175 patients. After construction of the tissue
microarray, every 30
th tissue microarray slide was evaluated by a
pathologist (H-J G). Both tumour and adjacent benign prostatic
hyperplasia (BPH) material could be analysed in 82 cases. In 49
cases, only carcinoma and in 44 cases only BPH could be analysed.
The median age at the time of diagnosis was 67 years (range 47–89).
Clinico-pathological data including Gleason score and pathological
staging according to the tumour node metastasis classification are
summarised in Table 1. For univariate statistical analysis, Gleason
scores were categorised as Gs5–6, Gs7, and Gs8–9 and pT-stage was
categorised as pT2 vs pT3–4. For multivariate statistical analysis,
clinico-pathological criteria were categorised into two groups each:
well to moderately differentiated tumours with Gleason scores 2–6
indicating a good prognosis were compared with poorly differ-
entiated tumours with Gleason scores 7–9 indicating more
aggressive tumours and a worse prognosis; pT-stage was categorised
as organ-confined (pT2) vs extraprostatic (pT3–pT4).
Analysis of genomic and expression data sets
To reveal the most abundant chromosomal imbalances detected in
prostate carcinoma, we performed an exhaustive search of six CGH
studies, including a total of 145 primary prostate cancers (Sattler
et al, 1999; Alers et al, 2001; Verdorfer et al, 2001; Zitzelsberger et al,
2001; Steiner et al,2 0 0 2 ;W o l t e ret al, 2002; Paris et al, 2003) as well
as one array CGH study of 16 primary prostate cancers (Paris et al,
2003). In order to identify candidate genes that may be directly
affected by these chromosomal imbalances, we screened a list of the
top 250 most up-regulated and down-regulated genes as revealed by
a recent meta-analysis of four independent expression microarrays
including 61 prostate cancer samples (Rhodes et al,2 0 0 2 ) .
Construction of a prostate carcinoma tissue microarray
Tissue microarrays were constructed as originally described
(Kononen et al, 1998). Briefly, representative tumour and benign
hyperplastic regions were marked by a pathologist (H-JG) on
haematoxylin and eosin (H&E) stained sections from each
paraffinised tumour block. Tissue cylinders with a diameter
of 0.6mm were punched from selected areas of each ‘donor’
block and transferred to a recipient paraffin block using a
tissue chip microarrayer (Beecher Instruments, Silver Spring,
MD, USA). Two to three tissue cores per tumour or BPH
sample were isolated and arrayed, summing up to a total of
651 tissue cores. According to previous studies (Nocito et al,
2001; Torhorst et al, 2001), this is sufficient to compensate for
the heterogeneous composition of prostate carcinomas in tissue
microarray analyses.
For immunohistochemistry (IHC) analyses, 5mm sections from
the recipient block were prepared. Sections from the front, the
middle and the rear part of the block were H&E stained and
reviewed again by a pathologist (H-JG) in order to distinguish
benign from malignant tissue.
Immunohistochemistry
Immunohistochemistry was performed using an avidin–biotin
complex (ABC) approach (Vectastain ABC Kit, Vector Labora-
tories Inc., Burlingame, CA, USA). Sections were deparaffinised
and epitopes were retrieved by heating in a microwave oven
with 10mM citrate buffer (pH 6.0) (for MYC: 10mM Tris, 1mM
ethylenediaminetetraacetic acid (EDTA), (pH 9.0) for 20min.
Endogenous peroxidase activity was inhibited by 3% hydrogen
peroxide. Unspecific binding was blocked with 1% normal serum
(for NM23-H1: 3% bovine serum albumin (BSA). Biotinylated anti-
rabbit, anti-mouse, anti-goat, and anti-sheep immunoglobulins
(Vector Laboratories Inc., Burlingame, CA, USA) were used as
secondary antibodies. For colour development, the specimens
were incubated with 3,30-diaminobenzidine hydrochloride (DAB)
supplemented with hydrogen peroxide (DAB Substrat kit, Linaris,
Wertheim-Bettingen, Germany) and afterwards counterstained
in haematoxylin. Primary anti-human antibodies were anti-NCL-
cMYC (9E11), mouse monoclonal diluted 1:175 (Novocastra
Laboratories Ltd, Newcastle, UK), anti-fatty acid synthase (FASN)
rabbit polyclonal diluted 1:150 (Assay Design Inc., Ann Arbor,
MI, USA), anti-BARK1 (5D5) mouse monoclonal diluted 1:300
(Invitrogen (Zymed), Paisley, UK), anti-NM23-H1 (NM301) mouse
monoclonal diluted 1:50, anti-PP1a (N-19) goat polyclonal diluted
1:150 and anti-PP2A (FL-309) rabbit polyclonal diluted 1:100
(Santa Cruz Biotechnology, Inc., CA, USA). Anti-PP2A does
not distinguish between the highly homologous (97%) a- and
b-isoforms of PP2A. Immunohistochemistry was performed on
consecutive sections. One section was immunostained with
anti-CK5 sheep polyclonal antibody (1:4000, The Binding Site,
Birmingham,UK) for cytokeratin 5, a specific marker for basal
cells, to distinguish benign from malignant glands in each tissue
core. Glandular tissue that had shown positive results in former
experiments served as positive control. Negative controls were
prepared by omitting the primary antibody.
Scoring of antibody staining
Cytoplasmic (MYC, BARK1, PP1a, PP2A, FASN) and nuclear
immunoreactivity (PP1a, PP2A, NM23-H1) were scored separately
according to staining intensity and graded semi-quantitatively
as negative ( ), weakly positive (þ), moderately positive (þþ),
and strongly positive (þþþ). For statistical analyses, the
immunostaining classifications were reduced to two categories:
negative and positive. The negative category included weakly
positive staining ( , þ) owing to the low numbers of completely
negatively stained samples. Each antibody was evaluated in a
double-blind fashion. The mean of all scores per specimen was
used as a single value for statistical analysis.
Table 1 Clinico-pathological features of 175 patients
a,b
Clinico-pathological
factor Classification
Tumour
(no. of cases
c)
BPH
d
(no. of cases
c)
Gleason score 2 2 2
423
51 52 5
63 03 4
73 12 4
83 62 1
996
Subtotal 125 115
pT-stage pT2 55 84
pT3 44 31
pT4 5 2
Subtotal 109 113
Total 131 126
BPH¼benign prostatic hyperplasias.
aOnly cases evaluated are listed above. Both
tumour material and BPH material could be analysed from 82 patients. Additionally,
carcinoma was analysable in 49 cases and BPH in another 44 cases.
bAge range 47–
89 years, median 67, mean 66.
cClinico-pathological data were not available for all
patients.
dBenign prostatic hyperplasias adjacent to tumours with the denoted stage
or Gleason score.
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Statistical analyses were performed using the statistical software
package SPSS 12.0 (SPSS GmbH Software, Munich, Germany).
Univariate analyses between immunohistochemical staining and
clinico-pathological variables were performed using w
2 and Fisher’s
exact tests. The familywise error rate was adjusted for 5% false
positives using Bonferroni–Holm correction from the software
package R, version 2.1.0. These error rates were independently
calculated for the clinico-pathological parameters Gleason
score and pT-stage. Yet, P-values mentioned in the text below
refer to the unadjusted P-values unless stated otherwise. For
multivariate analysis, binary logistic regression analysis together
with a moderate backward selection was applied to all patients,
from whom complete clinico-pathological data sets as well as IHC
results were available (significance level for staying in the model:
0.5). P-values p0.05 were considered as statistically significant in
all analyses.
RESULTS
Selection of candidate genes by correlation of genomic
and expression data sets
To establish a list of candidate genes relevant for prostate
carcinogenesis, we first performed an exhaustive search of six
previously published CGH analyses (145 primary prostate cancers)
and one array CGH analysis (16 primary prostate cancers) (see
Material and Methods). Copy number gains most frequently
affected regions on the chromosomal arms 17p, 8q, 7q, 3q, 7p, 17q,
1p, 19q, 20q, 16p, 11q, 12q, 19p, and 9q in declining frequency
(21 to 8%), whereas copy number losses particularly involved
subregions on 8p, 13q, 6q, 16q, 18q, 5q, 2q, and 4q in 28–9% of the
cases. In order to narrow down the range of possible candidate
genes from these regions, only the top 250 upregulated and
the top 250 downregulated genes in prostate carcinoma (Rhodes
et al, 2002) were further analysed in this study. We found 32 genes
located on frequently over represented bands and 28 genes
on frequently underrepresented bands (Supplementary Tables 2.1
and 2.2). These included MYC (8q24), BARK1 (11q13), meta-
stasis suppressor NM23-H1 (17q21), FASN (17q25) the catalytic
subunit of protein phosphatase PP1a encoded by PPP1CA (11q13)
as well as protein phosphatase PP2A (ß-isotype) encoded by
PPP2CB (8p11–p12). These genes were further analysed in
detail in a collection of prostate carcinomas using anti-
bodies, which had been established for immunhistochemical
detection against the corresponding proteins in paraffin-
embedded tissue material. The six candidate genes, their respective
chromosomal localisation as well as the frequency and rank of
genomic and expression alterations, respectively, are summarised
in Table 2.
Subcellular expression pattern of candidate proteins
Examples of typical staining patterns from the antibodies used are
shown in Figure 1. Fatty acid synthase immunostaining was
homogeneously dispersed throughout the cytoplasm as described
before (Swinnen et al, 2002; Rossi et al, 2003). Subcellular staining
of MYC was predominantly cytoplasmic: in BPH, perinuclear focal
granular immunostaining was observed on the luminal site of
the cells, whereas malignant secretory cells showed a diffuse
cytoplasmic immunostaining. This subcellular staining pattern is
in accordance with previous observations using the same antibody
in prostate cancer tissue (Jenkins et al, 1997). Beta-adrenergic
receptor kinase 1 immunostaining was observed in the cytoplasm
of glandular cells. Concerning PP1a and PP2A, a cytoplasmic as
well as a nuclear staining was observed. Cytoplasmic and nuclear
localisation of nm23-H1 were observed as recently shown in IHC
of the same antibody (Forus et al, 2001).
Correlation of protein expression and clinico-pathological
parameters using a prostate cancer tissue microarray
Univariate analyses In order to test whether the expression of the
selected proteins correlates with clinico-pathological parameters,
we constructed a tissue microarray. The tissue microarray
contained 651 analysable tissue cores from 131 different tumour
samples and 126 BPH from 175 prostate cancer patients.
Univariate analyses revealed a significant difference between
tumour and benign hyperplastic tissue for immunohistochemical
staining results of FASN (Po0.001), MYC (Po0.001), and PP1a
(P¼0.020), indicating a role of these proteins in tumour initiation
(Table 3).
Univariate correlations of protein expression with Gleason
score and pT-stage were found for MYC, BARK1 and PP1a
(Table 4, Figure 2), indicating a role of these proteins in tumour
progression. MYC immunostaining strongly decreased from
low to high Gleason scores as well as pT-stages (Po0.001 each).
Beta-adrenergic receptor kinase 1 immunostaining decreased from
low to high Gleason scores (P¼0.040). A negative correlation of
BARK1 immunostaining with Gleason score was also stated for the
benign hyperplastic tissue areas of the patients (P¼0.003). Protein
phosphatases PP1a immunostaining was constant in low and
intermediate Gleason scores (Gleason scores 5–7), but increased in
high Gleason scores (P¼0.001). For PP2A, FASN, and NM23-H1,
no correlations with the prognostic clinico-pathological para-
meters were stated in univariate analysis (Table 4). None of the
proteins analysed correlated with patient’s age (data not shown).
Table 2 Candidates for IHC analysis, derived by correlation of expression array data with CGH and array CGH data
Gene
a Gene name
a; alias
Chromosomal
location
CGH
b (n¼145),
gains
Array CGH
c
(n¼16), gains
Expression array meta-
analysis
d (n¼61), rank no.
e
NME1 Non-metastatic cells 1, protein (NM23a) expressed in 17q21.3 15.2% 2/16 1
FASN Fatty acid synthase; FAS, OA-519 17q25 20.7% 3/16 6
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 8q24.12–q24.13 15.2% 0/16 46
ADRBK1 Adrenergic, beta, receptor kinase 1; GRK2; BARK1 11q13 8.3% 3/16 131
PPP1CA Protein phosphatase 1, catalytic subunit, alpha isoform 11q13 8.3% 3/16 236
Deletions Deletions
PPP2CB Protein phosphatase 2 (formerly 2A), catalytic subunit,
beta isoform
8p12–p11.2 23.5% 5/16 66
CGH¼comparative genomic hybridisation; IHC¼immunohistochemistry.
aHUGO approved gene symbol and name.
bAlers et al (2001), Sattler et al (1999), Steiner et al
(2002), Verdorfer et al (2001), Wolter et al (2002) and Zitzelsberger et al (2001).
cParis et al (2003).
dRhodes et al (2002).
eRank in lists of the 500 most upregulated and
downregulated genes in prostate cancer vs benign prostate tissue.
Tissue microarray analysis of prostate cancer
I Prowatke et al
84
British Journal of Cancer (2007) 96(1), 82–88 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMultivariate analyses Logistic regression was used to predict the
outcome variables Gleason score (Gs2–6 vs Gs7–9) and pT-stage
(organ-confined vs extraprostatic) (Table 5). All proteins in this
study were included in the model. A moderate backward selection
was applied in order to exclude factors that were not relevant.
MYC, BARK1, and FASN protein expression were statistically
significant predictors of Gleason score (Po0.001, P¼0.023,
P¼0.036), representing tumour differentiation. High odds ratios
(OR) and 95% confidence intervals (CI) of MYC (OR¼7.143
[2.079–24.390]) and FASN (OR¼3.106 [1.035–9.259]) further
support their significant correlation with Gleason score. For
BARK1, odds ratio and 95% CI were not computable because
negative BARK1 immunostaining was exclusively found in patients
with high Gleason scores and never in cases with low Gleason
scores. Finally, MYC protein expression was the only factor
predicting pT-stage (Po0.001, OR¼6.993 (2.387–20.408)), that is
in agreement with the role of MYC in growth control.
In summary, logistic regression analysis identified MYC,
BARK1, and FASN protein expression predicting Gleason score.
MYC protein expression additionally predicted pT-stage.
DISCUSSION
The aim of this study was to identify proteins that might be of
potential biological and clinical relevance in the field of prostate
cancer. Six candidates, from whom antibodies for IHC analyses
are available, were analysed in detail in a large tumour collection
using tissue microarray technology: FASN, BARK1, PP1a, PP2A,
NM23-H1, and MYC.
Fatty acid synthase is an androgen-regulated enzyme required
for de-novo lipogenesis. Fatty acid synthase mRNA and protein
upregulation is one of the earliest and most common events in the
development of prostate carcinoma, and a strong association
between FASN and tumour initiation has been shown (Swinnen
et al, 2002; Rossi et al, 2003). Accordingly, we found FASN
expression to be much stronger in tumours than in BPH. Further,
FASN expression correlates with high Gleason scores in multi-
variate analysis, which is in accordance with previous reports
(Shurbaji et al, 1996). These results demonstrate the validity of our
experimental approach and further underline the role of FASN as a
molecular marker and therapeutic target in prostate cancer as
proposed previously (Baron et al, 2004).
b-adrenergic receptor kinase , the second candidate defined
in this study, has not been examined in the context of prostate
cancer progression before. b-adrenergic receptor kinase specifi-
cally desensitises agonist-occupied b-adrenergic receptors
(Pierce et al, 2002). Enhanced adrenergic receptor signalling
has been shown to be involved in the development of androgen-
independent prostate cancer cell proliferation (Kasbohm et al,
2005). We found tumours negative for BARK1 exclusively in
cases with high Gleason scores (Gs7–9). According to the
function of BARK1, a highly sensitise adrenergic receptors
and enhanced signalling would be expected under these condi-
tions. It would be of interest to test whether downregulation
of BARK1 may constitute a mechanism to trigger androgen-
independent tumour growth. Furthermore, negative BARK1
expression may indicate patients for which an androgen-ablation
therapy may be futile.
Two of the novel candidates analysed represent protein
phosphatases, PP1a and PP2A. Both are involved in signal
transduction, apoptosis, protein synthesis and intracellular trans-
port, RNA splicing, and cell-cycle regulation (Janssens and Goris,
2001; Garcia et al, 2003). The catalytic subunit of PP1a is located
on chromosomal band 11q13 that showed frequent gain in array
CGH analysis (Paris et al, 2003). Accordingly, we found enhanced
cytoplasmic PP1a immunostaining in tumours vs BPH. Further,
enhanced cytoplasmic PP1a immunostaining correlated with high
Negative
MYC
BARK1
FASN
PP1
PP2A
NM23-H1
Positive
Figure 1 Examples of immunohistochemical staining of MYC, BARK1,
FASN, PP1a, PP2A, and NM23-H1 on whole-tissue microarray cores
(0.6mm in diameter) and subcellular staining pattern (inserts). Negative
immunostaining: left column, positive immunostaining: right column. The
category of negative staining included weakly positive staining.
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progression.
Owing to their role as regulators of the cell cycle as well as in
apoptosis, protein phosphatases are increasingly discussed as
candidates for therapeutic interference (Berndt et al, 1997;
McCluskey et al, 2002). Inhibitors of protein phosphatases
exert anticancer activity and have already been used in the
treatment of primary hepatoma and upper gastrointestinal
carcinoma (Berndt et al, 1997; McCluskey et al, 2002). According
to the results presented, such inhibitors might be applicable in
future therapeutic strategies to prostate cancer after considering
the PP1a expression status. In contrast to PP1a, PPP2CB, a
catalytic subunit of PP2A, did not correlate with the clinico-
pathological factors analysed suggesting that PP2A does not play a
prominent role in prostate cancer.
Another candidate analysed in our study is the metastasis
suppressor NM23-H1, which is involved in the synthesis of
deoxynucleotides (Steeg, 2003). In prostate cancer, an inverse
relationship between NM23-H1 expression and metastatic status
was described, but a correlation with the progression of primary
tumours is controversially discussed (Konishi et al, 1993; Igawa et al,
1994). According to the present study, no correlation with clinico-
pathological parameters of primary prostate carcinomas was found.
In contrast, the sixth candidate, MYC, was not only found to be
differentially expressed in tumour vs BPH, but also correlated with
both Gleason score and pT-stage. Interestingly, MYC immuno-
staining decreased with tumour progression.
The c-myc gene is located on chromosome 8q, the gain of which
is an early event in prostate carcinogenesis (Alers et al, 2001).
Amplification of the c-myc locus 8q24 is linked to higher Gleason
scores (Qian et al, 2002) and a poor prognosis (Sato et al, 1999;
Tsuchiya et al, 2002). Concerning MYC protein expression, only
two studies have been published for prostate cancer tissue so far.
Royuela et al (2000) described MYC immunostaining to be positive
in prostate tumours and BPH (Jenkins et al, 1997; Royuela et al,
2000), which is in concordance with our observations. The second
study indicated that cytoplasmic immunostaining of MYC
increased with copy number gains of chromosome 8, which in
turn correlated with the occurrence of lymph node metastases
(Jenkins et al, 1997). Although a copy number gain would also
be expected for the tumours analysed in the present study, we
found a negative correlation of MYC immunostaining and tumour
progression.
Our data indicate that MYC protein expression is not primarily
dependent on chromosome 8 or c-myc gene copy number. This is
supported by various findings described in previous studies. Thus,
although a normal chromosomal complement can be expected in
BPH, like in normal prostate, MYC immunostaining was described
to be negative in normal prostate from young men but positive
in BPH (Royuela et al, 2000). Further, in prostate cancer cell
lines, MYC transcript levels were similar despite the fact that
the c-myc gene was amplified in some cell lines but not in others
(Tsuchiya et al, 2002). Finally, in human hepatocellular carcinoma,
a similar discrepancy between c-myc gene amplification and
Table 3 Immunostaining of all analysed proteins in BPH and prostate tumour samples
IHC positive staining (%) (n positive/n total)
No. of cases (n)M Y C
a BARK1
a PP1a
a FASN
a NM23-H1
b PP2A
a,b
Tumour (n¼131) 52% 93% 71% 54% 59% 54%
BPH (n¼126) 78% 92% 56% 15% 61% 56%
P-value o0.001 0.807 0.020 o0.001 0.685 0.891
Adjusted P-value
c o0.001 1.000 0.120 o0.001 1.000 1.000
BARK1¼b-adrenergic receptor kinase 1; FASN¼Fatty acid synthase; PP2A¼protein phosphatases.
aCytoplasmic immunostaining.
bNuclear immunostaining.
cIn order to
correct for multiple testing P-values were adjusted using Bonferroni–Holm correction.
Table 4 Correlation between clinico-pathological factors and positive immunostaining of all proteins analysed
Positive IHC staining (%) (n positive/n total)
No. of cases MYC
a BARK1
a PP1a
a FASN
a NM23-H1
b PP2A
a,b
Clinico-pathological
factor
Tumour
(n¼131)
BPH
(n¼126) Tumour BPH Tumour BPH Tumour BPH Tumour BPH Tumour BPH Tumour BPH
Gleason score
5–6 45 59 74% 80% 100% 100% 63% 51% 54% 16% 59% 55% 60% 60%
7 31 24 54% 74% 93% 87% 64% 55% 59% 18% 62% 71% 60% 61%
8–9 45 27 28% 68% 85% 78% 84% 68% 57% 14% 59% 76% 43% 50%
121
c 110
c
P-value o0.001 0.501 0.040 0.003 0.074
d 0.385 0.910 0.918 0.974 0.134 0.280 0.686
Adjusted P-value
e 0.002 1.000 0.240 0.024 0.052 1.000 1.000 1.000 1.000 0.804 1.000 1.000
pT-stage
pT2 60 80 73% 79% 96% 92% 66% 58% 59% 14% 61% 60% 55% 54%
pT3-pT4 49 33 36% 70% 93% 87% 73% 48% 63% 19% 60% 70% 55% 53%
109
c 113
c
P-value o0.001 0.324 0.657 0.477 0.515 0.392 0.832 0.556 1.000 0.375 1.000 1.000
Adjusted P-value
e 0.006 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
BARK1¼b-adrenergic receptor kinase 1; FASN¼Fatty acid synthase; PP2A¼protein phosphatases.
aCytoplasmic immunostaining.
bNuclear immunostaining.
cNo. of samples
for which the respective clinico-pathological data were available. Not all BPH samples correspond to the same patients as the tumour samples.
dFor Gleason scores 5–7 vs 8–9,
p¼0.001.
eP-values of Gleason score and pT-stage were corrected for multiple testing using Bonferroni-Holm for all proteins in this study.
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c-myc amplification, human hepatocellular carcinoma had less
nuclear and cytoplasmic MYC imunostaining than noncancerous
livers without c-myc amplification (Chan et al, 2004).
These findings implicate that MYC expression in prostate cancer
is not simply regulated by a gene dosage effect. We hypothesise
that MYC overexpression may be favourable for the proliferation
of benign hyperplastic cells, but may not be required for the
maintenance and progression of the tumour. It should also
be noted that MYC is not only involved in proliferation, but
also in apoptotic pathways (Chan et al, 2004). Therefore, if MYC is
downregulated during tumour progression as was observed in
the present study, this might reflect a mechanism to inhibit
MYC-activated apoptosis.
In conclusion, we showed that MYC immunostaining predicts
Gleason score and furthermore pT-stage, which represents the two
clinico-pathological parameters that correlate best with prostate
cancer-specific survival. However, the precise role of MYC in
prostate cancer progression needs further clarification.
The combined genomic and expression profiling analysis
described in this study suggested an upregulation of FASN,
BARK1, MYC, PP1a, and NM23-H1 expression and a down-
regulation of PP2A expression in prostate tumours. Indeed, such a
relation was observed for FASN and PP1a, indicating a gene dosage
effect, but not for the other candidate proteins examined. In fact,
multiple mechanisms contribute to the development and progres-
sion of prostate cancer. For example, genomic copy number
changes may initially result in an altered protein expression, but
this effect might be replaced by other mechanisms during later
phases of tumour development.
In conclusion, we demonstrated a novel approach providing
candidate genes of potential clinical and biological relevance.
Immunohistochemical analyses revealed several candidates corre-
lating with clinico-pathological factors that are markers for
prostate cancer-specific survival. The impact of the candidates
on prostate carcinogenesis and their potential clinical application
remain to be analysed in further detailed studies.
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Figure 2 Correlation of clinico-pathological parameters with immunostaining of MYC, BARK1 and PP1a in prostate tumour and BPH. MYC
immunostaining negatively correlated with Gleason score (A), and pT-stage (D) in tumour samples. Negative BARK1 immunostaining characterised a
subgroup of patients with high Gleason scores (B). Protein phosphatase1a immunostaining positively correlated with Gleason score (C) (Gs8–9 vs 5–7:
P¼0.001). P-values are derived from w
2test or Fisher’s exact test.
Table 5 Multivariate analyses for the prediction of clinico-pathological parameters by immunostaining results of MYC, BARK1, PP1a, PP2A, NM23-H1 and
FASN
Clinico-pathological factor Cases in analysis Results
a P-value
b OR (95% CI)
Gleason score (Gs2-6/Gs7-9) 82 MYC o0.001 7.143 (2.079–24.390)
BARK1 0.023 —
c
FASN 0.036 3.106 (1.035–9.259)
pT-stage (pT2/pT3-pT4) 77 MYC o0.001 6.993 (2.387–20.408)
BARK1¼b-adrenergic receptor kinase 1; FASN¼Fatty acid synthase; PP2A¼protein phosphatases.
aResults of logistic regression analysis with a moderate backward selection.
bP-value of likelyhood-ratio test.
cNumerically not computable as each of the eight negative BARK1 staining results was exclusively found in advanced Gleason scores (Gs7–9)
(see Table 4).
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